IN2012DN01478A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01478A IN2012DN01478A IN1478DEN2012A IN2012DN01478A IN 2012DN01478 A IN2012DN01478 A IN 2012DN01478A IN 1478DEN2012 A IN1478DEN2012 A IN 1478DEN2012A IN 2012DN01478 A IN2012DN01478 A IN 2012DN01478A
- Authority
- IN
- India
- Prior art keywords
- autophagy
- small molecule
- inhibitors
- inhibitor
- cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22716409P | 2009-07-21 | 2009-07-21 | |
US29673510P | 2010-01-20 | 2010-01-20 | |
PCT/US2010/042759 WO2011011522A2 (en) | 2009-07-21 | 2010-07-21 | Potent small molecule inhibitors of autophagy, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01478A true IN2012DN01478A (ru) | 2015-06-05 |
Family
ID=42829077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1478DEN2012 IN2012DN01478A (ru) | 2009-07-21 | 2010-07-21 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120258975A1 (ru) |
EP (1) | EP2456761A2 (ru) |
JP (1) | JP2013500255A (ru) |
KR (1) | KR20120100886A (ru) |
CN (1) | CN102574816A (ru) |
AU (1) | AU2010276223A1 (ru) |
BR (1) | BR112012001316A2 (ru) |
CA (1) | CA2767772A1 (ru) |
CL (1) | CL2012000163A1 (ru) |
IL (1) | IL217502A0 (ru) |
IN (1) | IN2012DN01478A (ru) |
MX (1) | MX2012000940A (ru) |
PE (1) | PE20120798A1 (ru) |
PH (1) | PH12012500097A1 (ru) |
RU (1) | RU2012105914A (ru) |
SG (1) | SG177486A1 (ru) |
WO (1) | WO2011011522A2 (ru) |
ZA (1) | ZA201201224B (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011031884A2 (en) * | 2009-09-10 | 2011-03-17 | Mayo Foundation For Medical Education And Research | Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides |
US8598344B2 (en) * | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
UA112197C2 (uk) * | 2011-09-13 | 2016-08-10 | Ігор Ронінсон | СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ АБО ПОРУШЕНЬ, СПРИЧИНЮВАНИХ ІНДУКОВАНОЮ ТРАНСКРИПЦІЙНОЮ АКТИВНІСТЮ NF-kB |
TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
KR20210007046A (ko) | 2013-02-01 | 2021-01-19 | 웰스태트 테러퓨틱스 코포레이션 | 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물 |
CN105143208B (zh) | 2013-02-21 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的喹唑啉 |
WO2014134169A1 (en) * | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
WO2014144752A1 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting chromatin modifiers for the treatment of medical conditions |
WO2014145512A2 (en) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Potent small molecule inhibitors of autophagy, and methods of use thereof |
US9393244B2 (en) | 2013-03-15 | 2016-07-19 | Georgetown University | Increasing parkin activity by administering a deubiquitinating enzyme inhibitor |
US11306328B2 (en) * | 2013-07-26 | 2022-04-19 | President And Fellows Of Harvard College | Genome engineering |
CN104164471A (zh) * | 2013-11-04 | 2014-11-26 | 复旦大学 | 基于细胞自噬的抗肿瘤药物的筛选方法 |
KR20180004242A (ko) * | 2015-05-08 | 2018-01-10 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 알쯔하이머병의 치료를 위한 뉴런 저장소-작동된 칼슘 진입 경로의 활성화 |
JP6740354B2 (ja) * | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
EP3184514A1 (en) * | 2015-12-23 | 2017-06-28 | Deutsches Krebsforschungszentrum | Autophagy inhibitors |
GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
CN108929373A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一种共价键修饰哺乳动物atg8 同源物的方法 |
EP3827001A1 (en) | 2018-07-26 | 2021-06-02 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
CN109721554A (zh) * | 2019-01-08 | 2019-05-07 | 贵州大学 | 一类4-氨基喹唑啉类化合物及其制备方法和应用 |
CA3143489A1 (en) * | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
US20210215710A1 (en) * | 2019-12-23 | 2021-07-15 | University Health Network | Methods for use of cdx2 as a biomarker to guide use of autophagy inhibitors in ovarian cancer |
WO2021178556A1 (en) | 2020-03-04 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for sensitization of tumor cells to immune therapy |
CN112608302B (zh) * | 2020-12-28 | 2022-05-24 | 郑州大学第一附属医院 | 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用 |
US11648254B2 (en) | 2021-03-02 | 2023-05-16 | Kumquat Biosciences Inc. | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling |
WO2023034411A1 (en) | 2021-09-01 | 2023-03-09 | Oerth Bio Llc | Compositions and methods for targeted degradation of proteins in a plant cell |
CN114224895B (zh) * | 2022-01-06 | 2023-06-30 | 山东农业大学 | 3-甲基腺嘌呤在清除牛乳腺上皮细胞内无乳链球菌中的应用 |
US11912708B2 (en) | 2022-04-20 | 2024-02-27 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
CN116179494B (zh) * | 2022-10-13 | 2024-01-26 | 武汉生物制品研究所有限责任公司 | 低成瘤性的mdck细胞株及其构建方法和应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS542325A (en) * | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
JPS542327A (en) * | 1977-06-07 | 1979-01-09 | Sankyo Co Ltd | Agricultural and horticultural pesticide |
GT198900008A (es) * | 1988-01-29 | 1990-07-17 | Derivados de quinolina, quinazolina y cinolina. | |
IL89027A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
US5227387A (en) * | 1991-09-03 | 1993-07-13 | Dowelanco | Quinoline nematicidal method |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US6262059B1 (en) * | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
DE10042060A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JP4389205B2 (ja) * | 2002-02-06 | 2009-12-24 | 宇部興産株式会社 | 4−アミノキナゾリン化合物の製法 |
JP2004059454A (ja) * | 2002-07-25 | 2004-02-26 | Japan Energy Corp | キナゾリン誘導体及びNF−κB活性化阻害剤 |
WO2005080352A2 (en) * | 2004-02-19 | 2005-09-01 | Rexahn Corporation | Quinazoline derivatives and therapeutic use thereof |
KR20060079121A (ko) * | 2004-12-31 | 2006-07-05 | 에스케이케미칼주식회사 | 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체 |
CA2595156A1 (en) | 2005-01-19 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
WO2008122038A1 (en) * | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
US8039502B2 (en) | 2007-07-24 | 2011-10-18 | The Ohio State University Research Foundation | Anti-infective agents against intracellular pathogens |
-
2010
- 2010-01-13 PH PH12012500097A patent/PH12012500097A1/en unknown
- 2010-07-21 CA CA2767772A patent/CA2767772A1/en not_active Abandoned
- 2010-07-21 CN CN2010800332736A patent/CN102574816A/zh active Pending
- 2010-07-21 EP EP10737435A patent/EP2456761A2/en not_active Withdrawn
- 2010-07-21 PE PE2012000085A patent/PE20120798A1/es not_active Application Discontinuation
- 2010-07-21 JP JP2012521755A patent/JP2013500255A/ja active Pending
- 2010-07-21 RU RU2012105914/04A patent/RU2012105914A/ru not_active Application Discontinuation
- 2010-07-21 WO PCT/US2010/042759 patent/WO2011011522A2/en active Application Filing
- 2010-07-21 AU AU2010276223A patent/AU2010276223A1/en not_active Abandoned
- 2010-07-21 SG SG2012000253A patent/SG177486A1/en unknown
- 2010-07-21 IN IN1478DEN2012 patent/IN2012DN01478A/en unknown
- 2010-07-21 BR BR112012001316A patent/BR112012001316A2/pt not_active IP Right Cessation
- 2010-07-21 KR KR1020127004431A patent/KR20120100886A/ko not_active Application Discontinuation
- 2010-07-21 MX MX2012000940A patent/MX2012000940A/es not_active Application Discontinuation
- 2010-07-21 US US13/382,572 patent/US20120258975A1/en not_active Abandoned
-
2012
- 2012-01-12 IL IL217502A patent/IL217502A0/en unknown
- 2012-01-20 CL CL2012000163A patent/CL2012000163A1/es unknown
- 2012-02-17 ZA ZA2012/01224A patent/ZA201201224B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013500255A (ja) | 2013-01-07 |
IL217502A0 (en) | 2012-02-29 |
CA2767772A1 (en) | 2011-01-27 |
EP2456761A2 (en) | 2012-05-30 |
PE20120798A1 (es) | 2012-07-27 |
WO2011011522A3 (en) | 2011-08-25 |
CN102574816A (zh) | 2012-07-11 |
WO2011011522A2 (en) | 2011-01-27 |
BR112012001316A2 (pt) | 2017-08-08 |
ZA201201224B (en) | 2012-10-31 |
PH12012500097A1 (en) | 2011-01-27 |
KR20120100886A (ko) | 2012-09-12 |
AU2010276223A1 (en) | 2012-03-08 |
US20120258975A1 (en) | 2012-10-11 |
RU2012105914A (ru) | 2013-08-27 |
SG177486A1 (en) | 2012-02-28 |
CL2012000163A1 (es) | 2012-07-13 |
MX2012000940A (es) | 2012-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01478A (ru) | ||
PH12012501747A1 (en) | Peptide epoxyketones for proteasome inhibition | |
MX2020009919A (es) | Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa. | |
NI201500024A (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis. | |
CL2012003503A1 (es) | Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos. | |
CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
EA201490161A1 (ru) | Соединения - ингибиторы сигналинга, опосредуемого рецептором notch | |
CL2007003758A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer. | |
CL2014001049A1 (es) | Compuestos derivados de purina sustituida, inhibidores de mtor; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento o prevencion del cancer, un trastorno neurodegenerativo o una enfermedad oftalmologica. | |
CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
EP3722810A3 (en) | Molecular profiling of tumors | |
JO3366B1 (ar) | مثبطات بيرازوليل كوينوكزالين كاينيز | |
GB201118656D0 (en) | New compounds | |
CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
UA108636C2 (xx) | Пептид | |
NZ717035A (en) | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | |
CL2011001943A1 (es) | Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso. | |
MX2009005938A (es) | 6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas. | |
GT201300263A (es) | Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor | |
CL2015000886A1 (es) | Compuestos derivados de azaindolinas sustituidas, inhibidores de la union de proteinas smac al inhibidor de proteinas de apoptosis (iap) y/o inhibidores de la union de proteina caspasa activada a los iap; composicion farmaceutica que los comprende; metodo para tratar o mejorar un cancer; y su uso para el tratamiento terapeutico y/o profilactico del cancer. | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
PH12017500270A1 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain | |
GEP20186900B (en) | Methods of treating cancer using aurora kinase inhibitors | |
CL2011003248A1 (es) | Composicion farmaceutica que comprende crf y un inhibidor de angiogenesis; util para la prevencion y el tratamiento del cancer. |